Printer Friendly

MEDIMMUNE'S RESPIGAM TO BE REVIEWED BY FDA ADVISORY COMMITTEE

 GAITHERSBURG, Md., Nov. 16 /PRNewswire/ -- MedImmune, Inc. (NASDAQ: MEDI) today announced that the agenda published in the Federal Register today for the Dec. 2, 1993 meeting of the Blood Products Advisory Committee for the United States Food and Drug Administration (FDA) includes a review of the application for marketing approval for RespiGam(TM). RespiGam, formerly Respivir(TM), is a polyclonal antibody product for the prevention of respiratory syncytial virus (RSV) infection in certain high risk infants. RSV is the leading cause of pneumonia and brouchiolitis in infants. A previously scheduled review at the Sept. 23, 1993 meeting of the Blood Products Advisory Committee had been postponed.
 MedImmune, Inc. was formed in 1988 to develop, manufacture and market therapeutics and vaccines for the treatment and prevention of certain infectious diseases and cancers. MedImmune's corporate headquarters are in Gaithersburg.
 -0- 11/16/93
 /CONTACT: David M. Mott, vice president-business development and planning, 301-417-0770 or Anthony J. Russo, Ph.D. or Rhonda Chiger of Noonan/Russo Communications, Inc., 212-696-4455/
 (MEDI)


CO: MedImmune, Inc. ST: Maryland IN: MTC SU:

LG -- NY038 -- 5013 11/16/93 11:07 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 16, 1993
Words:184
Previous Article:MFS ANNOUNCES 21ST METROPOLITAN NETWORK; ACQUIRES MWR FIBERCOM IN ST. LOUIS
Next Article:TELEFLEX AGREES TO ACQUIRE SURGICAL DEVICES MANUFACTURER EDWARD WECK INCORPORATED
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters